Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse ...

Two months after Bristol Myers Squibb fended off a lawsuit which accused the drugmaker of using illegal tactics to protect ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

Cigna sued Bristol Myers on Tuesday, accusing the drugmaker of violating federal antitrust law by maintaining a monopoly over ...

In this GEN panel discussion, three experts in cell and gene therapy development will share lessons and strategies learned ...

Phase 2 trial results support Isa-KRd as a standard treatment option for patients with high-risk, newly diagnosed multiple myeloma, according to researchers.

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety and promising objective response rates in patients with few treatment choices ...

Bachleda, PharmD, MBA appointed as independent member of the Board of Directors ; David Shook, MD appointed as Chief Medical Officer, Mark ...

Celgene launched Revlimid in 2005 at a price of $215 per pill. After more than 20 price hikes, the drug now costs $763 per pill, or $16,023 per month.

Amgen Inc. will pay $13.4 billion for a blockbuster psoriasis drug from Celgene Corp., which is shedding the asset in order to win antitrust regulators’ sign-off for Celgene’s $74-billion ...